Rituxan regulatory update

FDA granted breakthrough therapy designation to Rituxan rituximab to treat pemphigus vulgaris. Roche's Genentech unit is evaluating IV Rituxan in a Phase III trial for the indication. The chimeric mAb against CD20 antigen also has Orphan Drug designation from FDA for the indication...